The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
12 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,866,922 in first-year total cost, median $248,211.
Most frequent study sections
- Special Emphasis Panel[ZAI1 MC-M (S2)]2
- Special Emphasis Panel[ZAI1 AM-I (M1)]1
- Special Emphasis Panel[ZAI1 BJM-A (S1)]1
- Special Emphasis Panel[ZAI1 CAB-M (S1)]1
- Special Emphasis Panel[ZAI1 HSC-I (M1)]1
Most frequent institutions
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2
- JOHNS HOPKINS UNIVERSITY1
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE1
- PHAGEPRO, INC.1
- UNIV OF NORTH CAROLINA CHAPEL HILL1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2024 | miRNA profiling for monitoring and adjustment of immunosuppression in liver transplant recipients1R34AI174991-01A1 | SHAKED, ABRAHAM NA | UNIVERSITY OF PENNSYLVANIA, PA | $264,596 | ZAI1 |
| 2024 | A Phase 2C Randomized, Controlled, Open-Label Trial of Novel Shortened Regimens for the Treatment of Isoniazid-Monoresistant TB (IMR-TB)1R34AI179568-01 | VELASQUEZ, GUSTAVO EDUARDO | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $256,504 | ZAI1 |
| 2024 | Safety, immunogencity, and efficacy of PfSPZ LARC2 malaria vaccine in malaria-exposed adults and children1R34AI179569-01 | LAURENS, MATTHEW BRENT | UNIVERSITY OF MARYLAND BALTIMORE, MD | $250,796 | ZAI1 |
| 2024 | Preparation of a Phase I/II safety and efficacy trial for a cholera phage cocktail intervention1R34AI181650-01 | CAMILLI, ANDREWYEN, MINMIN | PHAGEPRO, INC., MA | $173,300 | ZAI1 |
| 2023 | iSYNAPSE: Early signals of the transition from immune quiescence to activation in the liver allograft microenvironment and in the circulation1R34AI174988-01 | FENG, SANDY | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $270,673 | ZAI1 |
| 2023 | Randomized Controlled Trial of Macrolide Therapy for Mycoplasma pneumoniae1R34AI174969-01 | AMBROGGIO, LILLIAM | UNIVERSITY OF COLORADO DENVER, CO | $266,860 | ZAI1 |
| 2023 | A prospective clinical trial of immunosuppression reduction in recipients of low eplet mismatched renal allografts: the kidney for life initiative1R34AI177209-01 | LONZE, BONNIE ELIZABETH | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $254,250 | ZAI1 |
| 2023 | Planning an antibiotic duration trial for acute graft pyelonephritis after kidney transplantation1R34AI170386-01A1 | VAN DUIN, DAVID | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $226,219 | ZAI1 |
| 2023 | Planning grant for CMV suppression to reduce mortality in hospitalized, HIV-exposed children1R34AI174980-01 | SLYKER, JENNIFER ANNWAMALWA, DALTON CHEKOKO | UNIVERSITY OF WASHINGTON, WA | $211,883 | ZAI1 |
| 2022 | The Averting Readmissions for Malaria and Outpatient Reinfections (ARMOR) Trial1R34AI165307-01 | IPPOLITO, MATTHEW MICHAEL | JOHNS HOPKINS UNIVERSITY, MD | $245,625 | ZAI1 |
| 2022 | Disulfiram for Entameoba histolytica Enteric Diarrhea [DEED] Trial1R34AI165304-01 | WARREN, CIRLE ALCANTARA | UNIVERSITY OF VIRGINIA, VA | $243,880 | ZAI1 |
| 2022 | Phase I/IIa Clinical Trial Using Localized and Systemic Delivery of the P2X7 Receptor Antagonist AZD9056 for the Treatment of Salivary Gland Dysfunction in Sjögren's Syndrome Patients1R34AI155318-01A1 | VISSINK, ARJANWEISMAN, GARY ANDREW | UNIVERSITY OF MISSOURI-COLUMBIA, MO | $202,336 | ZAI1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.